Kostial K, Piasek M, Blanusa M, Schönwald N, Jones M M, Singh P K
Department of Mineral Metabolism, Institute for Medical Research and Occupational Health, Zagreb, Republic of Croatia.
J Appl Toxicol. 1996 Mar-Apr;16(2):157-8. doi: 10.1002/(SICI)1099-1263(199603)16:2<157::AID-JAT322>3.0.CO;2-Q.
The cadmium mobilizing efficiency of a combined treatment with a novel cadmium chelating agent disodium N,N'-bis(D-glucosyl)-1,9-nonanediamine-N,N'-biscarbodithioate++ + (C9G2DTC) and with sodium N-benzyl-D-glucamine-N-carbodithioate (BGDTC) was evaluated in albino rats. They received 109Cd intraperitoneally once and 1 week later chelation therapy six times over 12 days at 2-day intervals. The treatment groups were: 1, control; 2, BGDTC six times; 3, C9G2DTC six times; 4, C9G2DTC three times followed by BGDTC three times; 5, C9G2DTC twice followed by BGDTC four times; 6, C9G2DTC once followed by BGDTC five times. The radioactivity in liver, kidney and brain was determined 19 days after 109Cd administration. Results were expressed as a percentage of the 109Cd dose and differences were analyzed by Duncan's multiple range test (P < 0.05). Treatment with C9G2DTC resulted in higher Cd reduction in the liver and lower in the kidney than with BGDTC, which is in agreement with our previous findings. Combined treatment resulted in a greater reduction of Cd in the liver and kidney than by using either chelating agent alone, irrespective of the number of C9G2DTC or BGDTC treatments, and without causing redistribution to the brain. The important aspect of this work is that C9G2DTC--the novel cadmium chelating agent which is extremely efficient in reducing Cd liver deposits and about three times more toxic than BGDTC--has to be used only once at the beginning of the treatment to obtain optimal reduction of aged organ cadmium deposits.
在白化大鼠中评估了新型镉螯合剂N，N'-双（D-葡萄糖基）-1,9-壬二胺-N，N'-双硫代氨基甲酸盐二钠（C9G2DTC）与N-苄基-D-葡糖胺-N-硫代氨基甲酸钠（BGDTC）联合治疗的镉动员效率。它们一次性腹腔注射109Cd，1周后每隔2天进行6次螯合治疗，共12天。治疗组如下：1，对照组；2，BGDTC治疗6次；3，C9G2DTC治疗6次；4，C9G2DTC治疗3次后再用BGDTC治疗3次；5，C9G2DTC治疗2次后再用BGDTC治疗4次；6，C9G2DTC治疗1次后再用BGDTC治疗5次。在给予109Cd后19天测定肝脏、肾脏和大脑中的放射性。结果以109Cd剂量的百分比表示，并通过邓肯多重极差检验分析差异（P<0.05）。与BGDTC相比，C9G2DTC治疗使肝脏中的镉减少量更高，而肾脏中的镉减少量更低，这与我们之前的研究结果一致。联合治疗导致肝脏和肾脏中的镉减少量比单独使用任何一种螯合剂都更大，无论C9G2DTC或BGDTC的治疗次数如何，并且不会导致镉重新分布到大脑。这项工作的重要方面是，C9G2DTC这种新型镉螯合剂在减少肝脏镉沉积方面极其有效，且毒性约为BGDTC的三倍，在治疗开始时只需使用一次就能实现老年器官镉沉积的最佳减少。
